MARK B WOODLAND MD
Prescription History 1477510337
Obstetrics & Gynecology in Reading, PA

NPI Status: Active since April 26, 2006

Contact Information

601 SPRUCE ST
READING, PA
ZIP 19611
Phone: (484) 628-8827
Fax: (215) 829-6553

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MARK B WOODLAND MD, an active Obstetrics & Gynecology specialist practicing in Reading, PA. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 91 documented patient claims. Among these therapy options, the most frequently utilized medication is Estradiol (Twice Weekly), which accounts for 29 claims alone.

Medication Index

No matching medications currently found on file.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 23
30-Day Fills 55.6
Days Supply 1,661
PA State Average Benchmarks
Peer Average Claims32.0
Peer Average 30-Day Fills73.8
Peer Average Days Supply2,193
Conservative Utilization

This provider writes prescriptions for this formulation 28.1% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,030.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$88.27

State Avg Cost Per Claim

$104.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Estradiol (Twice Weekly)

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 29
30-Day Fills 48.8
Days Supply 1,428
PA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills28.7
Peer Average Days Supply836
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 61.1% higher than the standard regional baseline profile for PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,737.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$94.41

State Avg Cost Per Claim

$107.53

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
PA State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills66.7
Peer Average Days Supply1,827
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.1% less volume than the regional standard for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,342.61 across this reporting matrix range.

Provider Avg Cost Per Claim

$485.69

State Avg Cost Per Claim

$554.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Premarin

Generic Formulation: Estrogens, ConjugatedSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 14
30-Day Fills 38.0
Days Supply 1,140
PA State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills47.0
Peer Average Days Supply1,391
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,579.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$612.81

State Avg Cost Per Claim

$402.19

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate.

Therapeutic Applications

This medication is a female hormone. It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment. Certain estrogen products may also be used by men and women to treat cancers (certain types of prostate cancer, breast cancer that has spread to other parts of the body) and by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure).

Spironolactone-Hctz

Generic Formulation: Spironolact/HydrochlorothiazidSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 14
30-Day Fills 22.0
Days Supply 660
PA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills49.0
Peer Average Days Supply1,435
Conservative Utilization

This provider writes prescriptions for this formulation 41.7% less frequently than the standard regional baseline metric for practitioners inside PA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $577.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$41.25

State Avg Cost Per Claim

$43.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat high blood pressure (hypertension), heart failure, or extra fluid in the body (edema). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This product contains two medications: spironolactone and hydrochlorothiazide. Both medications are water pills (diuretics) and cause your body to get rid of extra salt and water. This effect helps to relax the blood vessels so that blood can flow more easily and may increase the amount of urine you make when you first start the product. Spironolactone also helps to treat or prevent low blood potassium levels and block the activity of a certain natural substance (aldosterone) that can cause edema. Your doctor may direct you to start taking the individual medications first, and then switch you over to this combination product if this is the best dose combination for you.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MARK B WOODLAND MD provides transparency into local medical care patterns within Reading, PA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Obstetrics & Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.